However, a phase III trial in non-small-cell lung carcinoma (NSCLC) evaluating MAGE-A3 as an adjuvant treatment demonstrated no significant improvement in disease-free survival compared with placebo in MAGE-A3-positive patients. Here, MAGEA3 is linked to non-small cell lung carcinoma.